首页 > 最新文献

Journal of Critical Care Medicine最新文献

英文 中文
The implementation gap in critical care: From nutrition to ventilation. 重症监护的实施差距:从营养到通气。
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0011
Razvan Azamfirei
{"title":"The implementation gap in critical care: From nutrition to ventilation.","authors":"Razvan Azamfirei","doi":"10.2478/jccm-2025-0011","DOIUrl":"10.2478/jccm-2025-0011","url":null,"abstract":"","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"3-4"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of pre-existing sarcopenia on outcomes of critically ill patients treated for COVID-19. 先前存在的肌肉减少症对COVID-19危重患者治疗结果的影响
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2024-0045
Thomas Bradier, Sébastien Grigioni, Céline Savoye-Collet, Gaétan Béduneau, Dorothée Carpentier, Christophe Girault, Maximillien Grall, Grégoire Jolly, Najate Achamrah, Fabienne Tamion, Zoé Demailly

Background: Sarcopenia, defined by a loss of skeletal muscle mass and function, has been identified as a prevalent condition associated with poor clinical outcome among critically ill patients. This study aims to evaluate the impact of pre-existing sarcopenia on outcomes in critically ill patients with acute respiratory failure (ARF) due to COVID-19.

Material and methods: A retrospective study was carried out on COVID-19 patients admitted to intensive care. Pre-existing sarcopenia was assessed using early CT scans. Clinical outcomes, including duration of high-flow oxygenation (HFO), mechanical ventilation (MV), length of hospital stay (LOS) and ICU mortality, were evaluated according to sarcopenia status.

Results: Among the studied population, we found a high prevalence (75 patients, 50%) of pre-existing sarcopenia, predominantly in older male patients. Pre-existing sarcopenia significantly impacted HFO duration (6.8 (+/-4.4) vs. 5 (+/-2.9) days; p=0.005) but did not significantly affect MV requirement (21 (28%) vs. 23 (37.3%); p=185), MV duration (7 vs. 10 days; p=0.233), ICU mortality (12 (16%) vs. 10 (13.3 %); p=0.644) or hospital LOS (27 vs. 25 days; p=0.509). No differences in outcomes were observed between sarcopenic and non-sarcopenic obese patients.

Conclusions: Pre-existing sarcopenia in critically ill COVID-19 patients is associated with longer HFO duration but not with other adverse outcomes. Further research is needed to elucidate the mechanisms and broader impact of sarcopenia on septic critically ill patient outcomes.

背景:骨骼肌减少症的定义是骨骼肌质量和功能的丧失,已被确定为危重患者中与不良临床结果相关的一种普遍疾病。本研究旨在评估先前存在的肌肉减少症对COVID-19急性呼吸衰竭(ARF)危重患者预后的影响。材料与方法:对新冠肺炎重症监护患者进行回顾性研究。使用早期CT扫描评估先前存在的肌肉减少症。临床结果包括高流量氧合时间(HFO)、机械通气时间(MV)、住院时间(LOS)和ICU死亡率。结果:在研究人群中,我们发现先前存在的肌肉减少症患病率很高(75例,50%),主要发生在老年男性患者中。先前存在的肌肉减少症显著影响HFO持续时间(6.8(+/-4.4)天和5(+/-2.9)天;p=0.005),但对MV需要量无显著影响(21 (28%)vs. 23 (37.3%);p=185), MV持续时间(7天vs. 10天;p=0.233), ICU死亡率(12(16%)对10 (13.3%);p=0.644)或医院LOS (27 vs 25天;p = 0.509)。在肌肉减少和非肌肉减少的肥胖患者之间没有观察到结果的差异。结论:COVID-19危重患者先前存在的肌肉减少症与HFO持续时间延长有关,但与其他不良结局无关。需要进一步的研究来阐明肌肉减少症对脓毒症危重患者预后的机制和更广泛的影响。
{"title":"The effect of pre-existing sarcopenia on outcomes of critically ill patients treated for COVID-19.","authors":"Thomas Bradier, Sébastien Grigioni, Céline Savoye-Collet, Gaétan Béduneau, Dorothée Carpentier, Christophe Girault, Maximillien Grall, Grégoire Jolly, Najate Achamrah, Fabienne Tamion, Zoé Demailly","doi":"10.2478/jccm-2024-0045","DOIUrl":"10.2478/jccm-2024-0045","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenia, defined by a loss of skeletal muscle mass and function, has been identified as a prevalent condition associated with poor clinical outcome among critically ill patients. This study aims to evaluate the impact of pre-existing sarcopenia on outcomes in critically ill patients with acute respiratory failure (ARF) due to COVID-19.</p><p><strong>Material and methods: </strong>A retrospective study was carried out on COVID-19 patients admitted to intensive care. Pre-existing sarcopenia was assessed using early CT scans. Clinical outcomes, including duration of high-flow oxygenation (HFO), mechanical ventilation (MV), length of hospital stay (LOS) and ICU mortality, were evaluated according to sarcopenia status.</p><p><strong>Results: </strong>Among the studied population, we found a high prevalence (75 patients, 50%) of pre-existing sarcopenia, predominantly in older male patients. Pre-existing sarcopenia significantly impacted HFO duration (6.8 (+/-4.4) vs. 5 (+/-2.9) days; p=0.005) but did not significantly affect MV requirement (21 (28%) vs. 23 (37.3%); p=185), MV duration (7 vs. 10 days; p=0.233), ICU mortality (12 (16%) vs. 10 (13.3 %); p=0.644) or hospital LOS (27 vs. 25 days; p=0.509). No differences in outcomes were observed between sarcopenic and non-sarcopenic obese patients.</p><p><strong>Conclusions: </strong>Pre-existing sarcopenia in critically ill COVID-19 patients is associated with longer HFO duration but not with other adverse outcomes. Further research is needed to elucidate the mechanisms and broader impact of sarcopenia on septic critically ill patient outcomes.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"33-43"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Midodrine initiation criteria, dose titration, and adverse effects when administered to treat shock: A systematic review and semi-quantitative analysis. Midodrine治疗休克的起始标准、剂量滴定和不良反应:系统回顾和半定量分析。
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0007
Madeleine M Puissant, Kaitlin J Armstrong, Richard R Riker, Samir Haydar, Tania D Strout, Kathryn E Smith, David B Seder, David J Gagnon

Objective: Systematically examine the literature describing midodrine to treat shock and to summarize current administration and dosing strategies.

Data sources: Structured literature search conducted in MEDLINE (PubMed) from inception through May 10, 2023.

Study selection and data extraction: Abstracts and full texts were assessed for inclusion by two blinded, independent reviewers. English-language publications describing use of midodrine in adult patients with shock were included. Data were extracted by two blinded, independent abstractors using a standardized extraction tool. Quality assessments were completed by paired reviewers using JBI methodology.

Data synthesis: Fifteen of 698 (2%) screened manuscripts were included with 1,714 patients with a variety of shock types. Seven studies (47%) were retrospective, two (13%) prospective observational, and six (40%) randomized controlled studies. Midodrine was initiated to facilitate intravenous vasopressor (IVP) weaning in most (11, 73%) studies; only two (13%) reported IVP weaning protocol use. Starting doses were 10 mg every 8 hours (4, 27%) or three times a day (3, 20%), 20 mg every 8 hours (2, 13%); six studies (40%) did not report initial midodrine dosing. A midodrine titration protocol was reported in 6 (40%) studies. Thirteen (87%) studies evaluated for bradycardia, identified in 6 (46%) studies among 204 patients; only one (0.5%) patient required midodrine discontinuation. Three (20%) studies reported on hypertension with an incidence of 7-11%. Four (27%) studies assessed for ischemia; 5/1128 (0.4%) patients experienced mesenteric ischemia requiring midodrine discontinuation.

Relevance to patient care and clinical practice: This review explores the pragmatic details involved in initiating, titrating, and weaning midodrine for the bedside clinician and identifies rates of adverse events and complications.

Conclusions: Published literature describing midodrine use for shock is heterogeneous and comprised primarily of low or very low quality data. Future controlled trials addressing the shortcomings identified in this systematic review are warranted.

目的:系统地查阅有关midodrine治疗休克的文献,总结目前的给药和给药策略。数据来源:在MEDLINE (PubMed)中进行的结构化文献检索,从创立到2023年5月10日。研究选择和数据提取:摘要和全文由两名独立的盲法审稿人进行纳入评估。包括了描述midodrine在成年休克患者中使用的英文出版物。数据由两名独立的盲法提取者使用标准化的提取工具提取。质量评估由使用JBI方法的配对审稿人完成。数据综合:698篇筛选稿件中的15篇(2%)纳入了1714名不同休克类型的患者。7项研究(47%)为回顾性研究,2项(13%)为前瞻性观察研究,6项(40%)为随机对照研究。在大多数(11,73%)的研究中,Midodrine被用于促进静脉血管加压素(IVP)断奶;只有2例(13%)报告使用IVP断奶方案。起始剂量为每8小时10毫克(4.27%)或每天3次(3.20%),每8小时20毫克(2.13%);6项研究(40%)没有报告初始midodrine剂量。6项(40%)研究报告了midodrine滴定方案。13项(87%)研究评估了204例患者中6项(46%)研究中发现的心动过缓;只有1例(0.5%)患者需要停药。3项(20%)研究报告了高血压的发病率为7-11%。四项(27%)研究评估缺血;5/1128(0.4%)患者出现肠系膜缺血,需要停药。与患者护理和临床实践的相关性:本综述探讨了床边临床医生开始使用、滴定和停用midodrine的实用细节,并确定了不良事件和并发症的发生率。结论:已发表的描述midodrine用于休克的文献是不均匀的,主要由低质量或极低质量的数据组成。未来有必要进行对照试验,以解决本系统评价中发现的缺陷。
{"title":"Midodrine initiation criteria, dose titration, and adverse effects when administered to treat shock: A systematic review and semi-quantitative analysis.","authors":"Madeleine M Puissant, Kaitlin J Armstrong, Richard R Riker, Samir Haydar, Tania D Strout, Kathryn E Smith, David B Seder, David J Gagnon","doi":"10.2478/jccm-2025-0007","DOIUrl":"10.2478/jccm-2025-0007","url":null,"abstract":"<p><strong>Objective: </strong>Systematically examine the literature describing midodrine to treat shock and to summarize current administration and dosing strategies.</p><p><strong>Data sources: </strong>Structured literature search conducted in MEDLINE (PubMed) from inception through May 10, 2023.</p><p><strong>Study selection and data extraction: </strong>Abstracts and full texts were assessed for inclusion by two blinded, independent reviewers. English-language publications describing use of midodrine in adult patients with shock were included. Data were extracted by two blinded, independent abstractors using a standardized extraction tool. Quality assessments were completed by paired reviewers using JBI methodology.</p><p><strong>Data synthesis: </strong>Fifteen of 698 (2%) screened manuscripts were included with 1,714 patients with a variety of shock types. Seven studies (47%) were retrospective, two (13%) prospective observational, and six (40%) randomized controlled studies. Midodrine was initiated to facilitate intravenous vasopressor (IVP) weaning in most (11, 73%) studies; only two (13%) reported IVP weaning protocol use. Starting doses were 10 mg every 8 hours (4, 27%) or three times a day (3, 20%), 20 mg every 8 hours (2, 13%); six studies (40%) did not report initial midodrine dosing. A midodrine titration protocol was reported in 6 (40%) studies. Thirteen (87%) studies evaluated for bradycardia, identified in 6 (46%) studies among 204 patients; only one (0.5%) patient required midodrine discontinuation. Three (20%) studies reported on hypertension with an incidence of 7-11%. Four (27%) studies assessed for ischemia; 5/1128 (0.4%) patients experienced mesenteric ischemia requiring midodrine discontinuation.</p><p><strong>Relevance to patient care and clinical practice: </strong>This review explores the pragmatic details involved in initiating, titrating, and weaning midodrine for the bedside clinician and identifies rates of adverse events and complications.</p><p><strong>Conclusions: </strong>Published literature describing midodrine use for shock is heterogeneous and comprised primarily of low or very low quality data. Future controlled trials addressing the shortcomings identified in this systematic review are warranted.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"5-22"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choking and laryngospasm: Exploring commonalities and treatment strategies. 窒息和喉痉挛:探讨共性和治疗策略。
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0010
Gad Estis, Asia Estis-Deaton, Tiberiu Ezri
{"title":"Choking and laryngospasm: Exploring commonalities and treatment strategies.","authors":"Gad Estis, Asia Estis-Deaton, Tiberiu Ezri","doi":"10.2478/jccm-2025-0010","DOIUrl":"10.2478/jccm-2025-0010","url":null,"abstract":"","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"101-102"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of sleep quality on weaning from mechanical ventilation: A scoping review. 睡眠质量对机械通气断奶的影响:一项范围综述。
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2024-0043
Hana Locihová, Darja Jarošová, Karolína Šrámková, Jana Slonková, Renáta Zoubková, Klára Maternová, Karel Šonka

Introduction: Mechanically ventilated patients have disturbed sleep.

Aim of the study: To explore whether there is a relationship between successful or unsuccessful weaning of patients and their sleep quality and circadian rhythm.

Materials and methods: A scoping review. The search process involved four online databases: CINAHL, MEDLINE, ProQuest, and ScienceDirect. Original studies published between January 2020 and October 2022 were included in the review.

Results: Six studies met the inclusion criteria. These studies showed that patients with difficult weaning were more likely to have atypical sleep, shorter REM sleep, and reduced melatonin metabolite excretion. Muscle weakness was an independent factor associated with prolonged weaning from mechanical ventilation and was significantly more frequent in patients with atypical sleep. Heterogeneous patient samples and the methodology of the studies hamper a clear interpretation of the results.

Conclusions: A relationship was found between abnormal sleep patterns, reduced melatonin metabolite (6-sulfa-toxymelatonin) excretion, and unsuccessful weaning. However, the causality is not clear from the existing research.

简介:机械通气患者有睡眠障碍。研究目的:探讨断奶成功与否与患者睡眠质量和昼夜节律之间的关系。材料和方法:范围综述。搜索过程涉及四个在线数据库:CINAHL、MEDLINE、ProQuest和ScienceDirect。在2020年1月至2022年10月期间发表的原始研究被纳入该综述。结果:6项研究符合纳入标准。这些研究表明,断奶困难的患者更有可能出现非典型睡眠,快速眼动睡眠时间较短,褪黑激素代谢物排泄减少。肌肉无力是与机械通气延长脱机相关的独立因素,在非典型睡眠患者中更为常见。不同的患者样本和研究方法阻碍了对结果的清晰解释。结论:发现异常睡眠模式、褪黑激素代谢物(6-磺胺-羟褪黑激素)分泌减少和断奶不成功之间存在关系。然而,从现有的研究来看,其因果关系并不明确。
{"title":"Effect of sleep quality on weaning from mechanical ventilation: A scoping review.","authors":"Hana Locihová, Darja Jarošová, Karolína Šrámková, Jana Slonková, Renáta Zoubková, Klára Maternová, Karel Šonka","doi":"10.2478/jccm-2024-0043","DOIUrl":"10.2478/jccm-2024-0043","url":null,"abstract":"<p><strong>Introduction: </strong>Mechanically ventilated patients have disturbed sleep.</p><p><strong>Aim of the study: </strong>To explore whether there is a relationship between successful or unsuccessful weaning of patients and their sleep quality and circadian rhythm.</p><p><strong>Materials and methods: </strong>A scoping review. The search process involved four online databases: CINAHL, MEDLINE, ProQuest, and ScienceDirect. Original studies published between January 2020 and October 2022 were included in the review.</p><p><strong>Results: </strong>Six studies met the inclusion criteria. These studies showed that patients with difficult weaning were more likely to have atypical sleep, shorter REM sleep, and reduced melatonin metabolite excretion. Muscle weakness was an independent factor associated with prolonged weaning from mechanical ventilation and was significantly more frequent in patients with atypical sleep. Heterogeneous patient samples and the methodology of the studies hamper a clear interpretation of the results.</p><p><strong>Conclusions: </strong>A relationship was found between abnormal sleep patterns, reduced melatonin metabolite (6-sulfa-toxymelatonin) excretion, and unsuccessful weaning. However, the causality is not clear from the existing research.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"23-32"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraabdominal hypertension is less common than it used to be: A pilot step wedge trial. 腹内高血压不像以前那么常见了:一项先导步骤楔形试验。
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0002
Shane Smith, Fran Priestap, Neil Parry, Robert Arntfield, Patrick Murphy, Kelly Vogt, Ian Ball

Objective: This is a pilot study to determine the feasibility of a multicentre stepped wedge cluster randomized trial of implementing the 2013 World Society of the Intraabdominal Compartment Syndrome (WSACS) guidelines as an intervention to treat intraabdominal hypertension (IAH) and abdominal compartment syndrome (ACS) in critically ill patients.

Design: Single-centre before-and-after trial, with an observation / baseline period of 3 months followed by a 9-month intervention period.

Setting: A 35 bed medical-surgical-trauma intensive care unit in a tertiary level, Canadian hospital.

Patients: Recruitment from consecutively admitted adult intensive care unit patients.

Intervention: In the intervention period, treatment teams were prompted to implement WSACS interventions in all patients diagnosed with IAH.

Measurements and main results: 129 patients were recruited, 59 during the observation period and 70 during the intervention period. Only 17.0% and 12.9%, respectively, met diagnostic criteria for IAH. Many recruited patients did not have intraabdominal pressures measured regularly per study protocol. There was no difference in ICU mortality for patients in either cohort or between those with and without IAH.

Conclusions: The incidence of IAH in our patient population has decreased significantly since 2015. This is likely due to a significant change in routine care of critically ill patients, especially with respect to judicious goal-directed fluid resuscitation. Patient recruitment and protocol adherence in this study were low, exacerbated by other staffing and logistical pressures during the study period. We conclude that a larger multicentre trial is unlikely to yield evidence of a detectable treatment effect.

目的:这是一项试点研究,旨在确定实施2013年世界腹内隔室综合征协会(WSACS)指南作为治疗危重患者腹内高压(IAH)和腹内隔室综合征(ACS)的干预措施的多中心阶梯楔形聚类随机试验的可行性。设计:单中心前后试验,观察/基线期为3个月,干预期为9个月。环境:加拿大一家三级医院的35张病床的内科-外科-创伤重症监护室。患者:从连续住院的成人重症监护病房患者中招募。干预:在干预期间,对所有确诊为IAH的患者,提示各治疗小组实施WSACS干预。测量方法及主要结果:共纳入患者129例,其中观察期59例,干预期70例。分别只有17.0%和12.9%的患者符合IAH的诊断标准。许多入选的患者没有按照研究方案定期测量腹内压。两组患者的ICU死亡率以及有无IAH患者之间的死亡率均无差异。结论:自2015年以来,我们的患者人群中IAH的发生率明显下降。这可能是由于危重病人的常规护理发生了重大变化,特别是在明智的目标导向液体复苏方面。在这项研究中,患者招募和方案依从性较低,研究期间其他人员配备和后勤压力加剧了这一点。我们的结论是,一个更大的多中心试验不太可能产生可检测治疗效果的证据。
{"title":"Intraabdominal hypertension is less common than it used to be: A pilot step wedge trial.","authors":"Shane Smith, Fran Priestap, Neil Parry, Robert Arntfield, Patrick Murphy, Kelly Vogt, Ian Ball","doi":"10.2478/jccm-2025-0002","DOIUrl":"10.2478/jccm-2025-0002","url":null,"abstract":"<p><strong>Objective: </strong>This is a pilot study to determine the feasibility of a multicentre stepped wedge cluster randomized trial of implementing the 2013 World Society of the Intraabdominal Compartment Syndrome (WSACS) guidelines as an intervention to treat intraabdominal hypertension (IAH) and abdominal compartment syndrome (ACS) in critically ill patients.</p><p><strong>Design: </strong>Single-centre before-and-after trial, with an observation / baseline period of 3 months followed by a 9-month intervention period.</p><p><strong>Setting: </strong>A 35 bed medical-surgical-trauma intensive care unit in a tertiary level, Canadian hospital.</p><p><strong>Patients: </strong>Recruitment from consecutively admitted adult intensive care unit patients.</p><p><strong>Intervention: </strong>In the intervention period, treatment teams were prompted to implement WSACS interventions in all patients diagnosed with IAH.</p><p><strong>Measurements and main results: </strong>129 patients were recruited, 59 during the observation period and 70 during the intervention period. Only 17.0% and 12.9%, respectively, met diagnostic criteria for IAH. Many recruited patients did not have intraabdominal pressures measured regularly per study protocol. There was no difference in ICU mortality for patients in either cohort or between those with and without IAH.</p><p><strong>Conclusions: </strong>The incidence of IAH in our patient population has decreased significantly since 2015. This is likely due to a significant change in routine care of critically ill patients, especially with respect to judicious goal-directed fluid resuscitation. Patient recruitment and protocol adherence in this study were low, exacerbated by other staffing and logistical pressures during the study period. We conclude that a larger multicentre trial is unlikely to yield evidence of a detectable treatment effect.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"95-100"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors and outcomes of critically ill pregnant COVID-19 patients: Experience from the first and second waves of the pandemic. COVID-19危重妊娠患者的危险因素和结局:第一波和第二波大流行的经验
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0008
Dita Aditianingsih, Noor Hafidz, Aino Nindya Auerkari, Zarah Tin Cahyaningrum, El Nissi Leonard, Chrisella Annabelle

Introduction: Understanding the association between risk factors and clinical outcomes of COVID-19 can lead to identifying suitable management strategies for reducing the mortality rate among maternal COVID-19 patients in the ICU.

Aim of the study: This study aims to investigate the clinical outcomes and risk factors associated with pregnant and postpartum women diagnosed with COVID-19 and admitted to the intensive care unit (ICU) between May 2020 and September 2021.

Materials and methods: This retrospective cohort study was conducted at the Universitas Indonesia Hospital. Secondary data was collected from the medical records to include all pregnant and postpartum women diagnosed with confirmed COVID-19 admitted to the hospital during the research period.

Results: The study included 113 patients and found that admission to the ICU, age, and gestational age significantly influenced clinical outcomes, with a mortality rate of 42.11% among ICU-admitted patients. Pre-existing comorbidities such as type-2 diabetes mellitus, congestive heart failure, and coronary artery disease were associated with ICU admission. Having at least one comorbidity was found to increase the mortality rate by six-fold.

Conclusions: The study emphasizes the importance of monitoring and evaluating maternal and fetal complications during COVID-19 infection, highlighting the need for multidisciplinary management involving intensivists, obstetricians, anesthesiologists, and infectious disease specialists. The findings underscore the significance of baseline health status in treatment planning and the potential for evidence-based interventions to improve maternal outcomes and pregnancy preservation. Further research is warranted to validate these results and enhance understanding of the underlying pathophysiology.

前言:了解COVID-19危险因素与临床结局之间的关系,有助于确定合适的管理策略,降低ICU孕产妇COVID-19患者的死亡率。研究目的:本研究旨在调查2020年5月至2021年9月期间诊断为COVID-19并入住重症监护病房(ICU)的孕妇和产后妇女的临床结局和相关危险因素。材料和方法:本回顾性队列研究在印度尼西亚大学医院进行。从医疗记录中收集二次数据,包括研究期间住院的所有确诊为COVID-19的孕妇和产后妇女。结果:本研究纳入113例患者,发现入住ICU、年龄、胎龄对临床结局有显著影响,入住ICU患者的死亡率为42.11%。先前存在的合并症,如2型糖尿病、充血性心力衰竭和冠状动脉疾病与ICU住院有关。发现至少有一种合并症会使死亡率增加6倍。结论:本研究强调了监测和评估COVID-19感染期间母婴并发症的重要性,强调了重症医师、产科医生、麻醉师和传染病专家参与多学科管理的必要性。研究结果强调了基线健康状况在治疗计划中的重要性,以及基于证据的干预措施在改善孕产妇结局和妊娠保护方面的潜力。需要进一步的研究来验证这些结果,并加强对潜在病理生理学的理解。
{"title":"Risk factors and outcomes of critically ill pregnant COVID-19 patients: Experience from the first and second waves of the pandemic.","authors":"Dita Aditianingsih, Noor Hafidz, Aino Nindya Auerkari, Zarah Tin Cahyaningrum, El Nissi Leonard, Chrisella Annabelle","doi":"10.2478/jccm-2025-0008","DOIUrl":"10.2478/jccm-2025-0008","url":null,"abstract":"<p><strong>Introduction: </strong>Understanding the association between risk factors and clinical outcomes of COVID-19 can lead to identifying suitable management strategies for reducing the mortality rate among maternal COVID-19 patients in the ICU.</p><p><strong>Aim of the study: </strong>This study aims to investigate the clinical outcomes and risk factors associated with pregnant and postpartum women diagnosed with COVID-19 and admitted to the intensive care unit (ICU) between May 2020 and September 2021.</p><p><strong>Materials and methods: </strong>This retrospective cohort study was conducted at the Universitas Indonesia Hospital. Secondary data was collected from the medical records to include all pregnant and postpartum women diagnosed with confirmed COVID-19 admitted to the hospital during the research period.</p><p><strong>Results: </strong>The study included 113 patients and found that admission to the ICU, age, and gestational age significantly influenced clinical outcomes, with a mortality rate of 42.11% among ICU-admitted patients. Pre-existing comorbidities such as type-2 diabetes mellitus, congestive heart failure, and coronary artery disease were associated with ICU admission. Having at least one comorbidity was found to increase the mortality rate by six-fold.</p><p><strong>Conclusions: </strong>The study emphasizes the importance of monitoring and evaluating maternal and fetal complications during COVID-19 infection, highlighting the need for multidisciplinary management involving intensivists, obstetricians, anesthesiologists, and infectious disease specialists. The findings underscore the significance of baseline health status in treatment planning and the potential for evidence-based interventions to improve maternal outcomes and pregnancy preservation. Further research is warranted to validate these results and enhance understanding of the underlying pathophysiology.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"54-63"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypercapnia outcome in COVID-19 acute respiratory distress syndrome patients on mechanical ventilator: A retrospective observational cohort. 使用机械呼吸机的COVID-19急性呼吸窘迫综合征患者高碳酸血症结局:回顾性观察队列
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0004
Sarwat Rasheed, Sidra Javed, Thanyat Rasheed, Shaiza Farman, Elisha Shalim

Introduction: Acute respiratory distress syndrome (ARDS) is characterized by progressive lung inflammation which leads to increased dead space that can cause hypercapnia and can increase the risk of patient morbidity and mortality. In an attempt to improve ARDS patient outcomes provision of protective lung ventilation has been shown to improve patient mortality but increases the incidence of hypercapnia. Therefore, the role of carbon dioxide in ARDS remains contradicted by conflicted evidence. This study aims to examine this conflicting relationship between hyper-capnia and mortality in mechanically ventilated COVID-19 ARDS patients.

Methods: We conducted a retrospective cohort study. The data was collected from the medical records of the patients admitted with COVID-19 ARDS in Sindh Infectious Disease Hospital & Research Centre (SIDH & RC) from August 2020 to August 2022 and who received mechanical ventilation for more than 48 hours. The patients were grouped into severe and no severe hypercapnia groups based on their arterial blood carbon dioxide levels (PaCO2). To understand the effect of hypercapnia on mortality we performed multivariable logistic regression, and inverse probability-weighted regression to adjust for time-varying confounders.

Results: We included 288 patients to detect at least 3% of the effect on mortality. Our analysis revealed an association of severe hypercapnia with severe lung injury, low PaO2/FiO2, high dead space, and poor compliance. In univariate analysis severe hypercapnia showed higher mortality: OR=3.50, 95% CI (1.46-8.43). However, after, adjusting for disease severity hypercapnia is not found to be associated with mortality: OR=1.08, 95% CI (0.32-3.64). The sensitive analysis with weighted regression also shows no significant effect on mortality: OR=1.04, 95% CI (0.95-1.14).

Conclusion: This study showed that hypercapnia is not associated with mortality in COVID-19 ARDS patients.

简介急性呼吸窘迫综合征(ARDS)的特点是进行性肺部炎症导致死腔增加,从而引起高碳酸血症,增加患者发病和死亡的风险。为了改善 ARDS 患者的预后,已证明提供保护性肺通气可改善患者死亡率,但会增加高碳酸血症的发生率。因此,二氧化碳在 ARDS 中的作用仍然存在证据矛盾。本研究旨在研究机械通气 COVID-19 ARDS 患者高碳酸血症与死亡率之间的矛盾关系:我们进行了一项回顾性队列研究。数据来自信德传染病医院和研究中心(SIDH & RC)2020 年 8 月至 2022 年 8 月期间收治的 COVID-19 ARDS 患者的病历,这些患者接受机械通气的时间超过 48 小时。根据动脉血二氧化碳水平(PaCO2)将患者分为严重高碳酸血症组和非严重高碳酸血症组。为了解高碳酸血症对死亡率的影响,我们进行了多变量逻辑回归和反概率加权回归,以调整随时间变化的混杂因素:我们纳入了 288 名患者,以检测至少 3% 的死亡率影响。我们的分析表明,严重高碳酸血症与严重肺损伤、低 PaO2/FiO2、高死腔和顺应性差有关。在单变量分析中,严重高碳酸血症显示死亡率较高:OR=3.50,95% CI(1.46-8.43)。然而,在对疾病严重程度进行调整后,发现高碳酸血症与死亡率无关:OR=1.08,95% CI(0.32-3.64)。加权回归的敏感性分析也显示,高碳酸血症对死亡率没有显著影响:结论:本研究表明,高碳酸血症与 COVID-19 ARDS 患者的死亡率无关。
{"title":"Hypercapnia outcome in COVID-19 acute respiratory distress syndrome patients on mechanical ventilator: A retrospective observational cohort.","authors":"Sarwat Rasheed, Sidra Javed, Thanyat Rasheed, Shaiza Farman, Elisha Shalim","doi":"10.2478/jccm-2025-0004","DOIUrl":"10.2478/jccm-2025-0004","url":null,"abstract":"<p><strong>Introduction: </strong>Acute respiratory distress syndrome (ARDS) is characterized by progressive lung inflammation which leads to increased dead space that can cause hypercapnia and can increase the risk of patient morbidity and mortality. In an attempt to improve ARDS patient outcomes provision of protective lung ventilation has been shown to improve patient mortality but increases the incidence of hypercapnia. Therefore, the role of carbon dioxide in ARDS remains contradicted by conflicted evidence. This study aims to examine this conflicting relationship between hyper-capnia and mortality in mechanically ventilated COVID-19 ARDS patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study. The data was collected from the medical records of the patients admitted with COVID-19 ARDS in Sindh Infectious Disease Hospital & Research Centre (SIDH & RC) from August 2020 to August 2022 and who received mechanical ventilation for more than 48 hours. The patients were grouped into severe and no severe hypercapnia groups based on their arterial blood carbon dioxide levels (PaCO2). To understand the effect of hypercapnia on mortality we performed multivariable logistic regression, and inverse probability-weighted regression to adjust for time-varying confounders.</p><p><strong>Results: </strong>We included 288 patients to detect at least 3% of the effect on mortality. Our analysis revealed an association of severe hypercapnia with severe lung injury, low PaO2/FiO2, high dead space, and poor compliance. In univariate analysis severe hypercapnia showed higher mortality: OR=3.50, 95% CI (1.46-8.43). However, after, adjusting for disease severity hypercapnia is not found to be associated with mortality: OR=1.08, 95% CI (0.32-3.64). The sensitive analysis with weighted regression also shows no significant effect on mortality: OR=1.04, 95% CI (0.95-1.14).</p><p><strong>Conclusion: </strong>This study showed that hypercapnia is not associated with mortality in COVID-19 ARDS patients.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"44-53"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What proteins and albumins in bronchoalveolar lavage fluid and serum could tell us in COVID-19 and influenza acute respiratory distress syndrome on mechanical ventilation patient - A prospective double center study. 支气管肺泡灌洗液和血清中蛋白质和白蛋白对机械通气患者COVID-19和流感急性呼吸窘迫综合征的意义——一项前瞻性双中心研究
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0005
Anita Djurdjevic Svraka, Dragan Svraka, Bosa Mrjanic Azaric, Jovana Malic, Goran Baric, Pedja Kovacevic

Introduction: The extent of in vivo damage to the alveolar-capillary membrane in patients with primary lung injury remains unclear. In cases of ARDS related to COVID-19 and Influenza type A, the complexity of the damage increases further, as viral pneumonia cannot currently be treated with a causal approach.

Aims of the study: Our primary goal is to enhance the understanding of Acute Respiratory Distress Syndrome (ARDS) by demonstrating damage to the alveocapillary membrane in critically ill patients with COVID-19 and influenza type A. We will achieve this by measuring the levels of proteins and albumin in bronchoalveolar fluid (BAL) and serum. Our secondary objective is to assess patient outcomes related to elevated protein and albumin levels in both BAL and blood serum, which will deepen our understanding of this complex condition.

Materials and methods: Bronchoalveolar lavage (BAL) fluid and serum samples were meticulously collected from a total of 64 patients, categorized into three distinct groups: 30 patients diagnosed with COVID-19-related acute respiratory distress syndrome (ARDS), 14 patients with influenza type A (H1N1 strain), also experiencing ARDS, and a control group consisting of 20 patients who were preoperatively prepared for elective surgical procedures without any diagnosed lung disease. The careful selection and categorization of patients ensure the robustness of our study. BAL samples were taken within the first 24 hours following the commencement of invasive mechanical ventilation in the intensive care unit, alongside measurements of serum albumin levels. In the control group, BAL and serum samples were collected after the induction of general endotracheal anaesthesia.

Results: Patients in the COVID-19 group are significantly older than those in the Influenza type A (H1N1) group, with median ages of 72.5 years and 62 years, respectively (p < 0.01, Mann-Whitney U test). Furthermore, serum albumin levels (measured in g/L) revealed significant differences across all three groups in the overall sample, yielding a p-value of less than 0.01 according to ANOVA. In terms of treatment outcomes, serum albumin levels also exhibited a significant correlation, with a p-value of 0.03 (Mann-Whitney U test). A reduction in serum albumin levels (below 35 g/L), combined with elevated protein levels in bronchoalveolar lavage (BAL), serves as a predictor of poor outcomes in patients with acute respiratory distress syndrome (ARDS), as indicated by a p-value of less than 0.01 (ANOVA).

Conclusions: Our findings indicate that protein and albumin levels in bronchoalveolar lavage (BAL) fluid are elevated in severe acute respiratory distress syndrome (ARDS) cases. This suggests that BAL can effectively evaluate protein levels and fractions, which could significantly assist in assessing damage to the alveolocapillary membrane. Additionally, t

简介:原发性肺损伤患者肺泡毛细血管膜的体内损伤程度尚不清楚。在与COVID-19和甲型流感相关的急性呼吸窘迫综合征病例中,损害的复杂性进一步增加,因为病毒性肺炎目前无法用因果关系方法治疗。研究目的:我们的主要目标是通过展示COVID-19和a型流感危重患者的肺泡毛细血管膜损伤来增强对急性呼吸窘迫综合征(ARDS)的认识。我们将通过测量支气管肺泡液(BAL)和血清中的蛋白质和白蛋白水平来实现这一目标。我们的次要目标是评估与BAL和血清中蛋白和白蛋白水平升高相关的患者结局,这将加深我们对这种复杂疾病的理解。材料和方法:仔细收集64例患者的支气管肺泡灌洗(BAL)液和血清样本,将其分为三组:30例诊断为covid -19相关急性呼吸窘迫综合征(ARDS)的患者,14例同样患有ARDS的a型流感(H1N1毒株)患者,以及20例术前准备进行选择性手术且未诊断出任何肺部疾病的对照组。患者的仔细选择和分类确保了我们研究的稳健性。在重症监护室开始有创机械通气后的头24小时内采集BAL样本,同时测量血清白蛋白水平。对照组在气管内全麻诱导后采集BAL和血清样本。结果:新冠肺炎组患者年龄明显大于甲型H1N1流感组,中位年龄分别为72.5岁和62岁(p < 0.01, Mann-Whitney U检验)。此外,血清白蛋白水平(以g/L测量)在整个样本中显示出三组之间的显著差异,根据方差分析,p值小于0.01。在治疗结果方面,血清白蛋白水平也表现出显著的相关性,p值为0.03 (Mann-Whitney U检验)。血清白蛋白水平降低(低于35 g/L),同时支气管肺泡灌洗(BAL)中蛋白质水平升高,可作为急性呼吸窘迫综合征(ARDS)患者预后不良的预测因子,其p值小于0.01(方差分析)。结论:我们的研究结果表明,在严重急性呼吸窘迫综合征(ARDS)病例中,支气管肺泡灌洗液(BAL)中的蛋白质和白蛋白水平升高。这表明BAL可以有效地评估蛋白水平和组分,这可以显著帮助评估肺泡毛细血管膜的损伤。此外,BAL中白蛋白水平的升高,通常伴随着血清白蛋白水平的降低,可能作为ARDS肺泡毛细血管膜完整性受损的有价值的指标,对患者护理具有潜在的意义。
{"title":"What proteins and albumins in bronchoalveolar lavage fluid and serum could tell us in COVID-19 and influenza acute respiratory distress syndrome on mechanical ventilation patient - A prospective double center study.","authors":"Anita Djurdjevic Svraka, Dragan Svraka, Bosa Mrjanic Azaric, Jovana Malic, Goran Baric, Pedja Kovacevic","doi":"10.2478/jccm-2025-0005","DOIUrl":"10.2478/jccm-2025-0005","url":null,"abstract":"<p><strong>Introduction: </strong>The extent of in vivo damage to the alveolar-capillary membrane in patients with primary lung injury remains unclear. In cases of ARDS related to COVID-19 and Influenza type A, the complexity of the damage increases further, as viral pneumonia cannot currently be treated with a causal approach.</p><p><strong>Aims of the study: </strong>Our primary goal is to enhance the understanding of Acute Respiratory Distress Syndrome (ARDS) by demonstrating damage to the alveocapillary membrane in critically ill patients with COVID-19 and influenza type A. We will achieve this by measuring the levels of proteins and albumin in bronchoalveolar fluid (BAL) and serum. Our secondary objective is to assess patient outcomes related to elevated protein and albumin levels in both BAL and blood serum, which will deepen our understanding of this complex condition.</p><p><strong>Materials and methods: </strong>Bronchoalveolar lavage (BAL) fluid and serum samples were meticulously collected from a total of 64 patients, categorized into three distinct groups: 30 patients diagnosed with COVID-19-related acute respiratory distress syndrome (ARDS), 14 patients with influenza type A (H1N1 strain), also experiencing ARDS, and a control group consisting of 20 patients who were preoperatively prepared for elective surgical procedures without any diagnosed lung disease. The careful selection and categorization of patients ensure the robustness of our study. BAL samples were taken within the first 24 hours following the commencement of invasive mechanical ventilation in the intensive care unit, alongside measurements of serum albumin levels. In the control group, BAL and serum samples were collected after the induction of general endotracheal anaesthesia.</p><p><strong>Results: </strong>Patients in the COVID-19 group are significantly older than those in the Influenza type A (H1N1) group, with median ages of 72.5 years and 62 years, respectively (p < 0.01, Mann-Whitney U test). Furthermore, serum albumin levels (measured in g/L) revealed significant differences across all three groups in the overall sample, yielding a p-value of less than 0.01 according to ANOVA. In terms of treatment outcomes, serum albumin levels also exhibited a significant correlation, with a p-value of 0.03 (Mann-Whitney U test). A reduction in serum albumin levels (below 35 g/L), combined with elevated protein levels in bronchoalveolar lavage (BAL), serves as a predictor of poor outcomes in patients with acute respiratory distress syndrome (ARDS), as indicated by a p-value of less than 0.01 (ANOVA).</p><p><strong>Conclusions: </strong>Our findings indicate that protein and albumin levels in bronchoalveolar lavage (BAL) fluid are elevated in severe acute respiratory distress syndrome (ARDS) cases. This suggests that BAL can effectively evaluate protein levels and fractions, which could significantly assist in assessing damage to the alveolocapillary membrane. Additionally, t","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"64-69"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of monitoring critical ill children with traumatic brain injury. 颅脑损伤危重症患儿监护效果评价。
IF 0.9 Q4 CRITICAL CARE MEDICINE Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI: 10.2478/jccm-2025-0001
Merve Misirlioglu, Dincer Yildizdas, Faruk Ekinci, Ozden Ozgur Horoz, Gulen Gul Mert

Introduction: In traumatic brain injury (TBI), direct information can be obtained about cerebral blood flow, brain tissue oxygenation and cerebral perfusion pressure values. More importantly, an idea about the changes in these measurements can be obtained with multidimensional monitoring and widely used monitoring methods.

Aim of the study: We aimed to evaluate the monitoring of critically ill children who were followed up in our pediatric intensive care unit (PICU) due to TBI.

Material and method: Twenty-eight patients with head trauma who were followed up in our tertiary PICU between 2018 and 2020 were included in the study. Cerebral tissue oxygenation, optic nerve sheath diameter (ONSD), Glasgow coma score (GCS) and Glasgow Outcome Score (GOSE) values were obtained from retrospective file records and examined.

Results: Male gender was 71.4% (n=20). When we classified TBI according to GCS, 50% (n=14) had moderate TBI and 50% had severe TBI. On the first day in the poor prognosis group, ONSD and nICP were found to be higher than in the good prognosis group (for ONSD, p=0.01; and for nICP, p=0.004). On the second day of hospitalization, the ONSD and nICP were significantly higher in the poor prognosis group than in the good prognosis group (for ONSD p=0.002; and for nICP p= 0.001). Cerebral tissue oxygenation values measured on the first and second days decreased significantly on the second day in both the good and poor prognosis groups (p=0.03, 0.006). In the good prognosis group, a statistically significant decrease was found in ONSD and nICP measurements taken on the 2nd day compared to the measurements taken at the time of hospitalization (for ONSD p=0.004; for nICP p<0.001).

Conclusion: The aim of multidimensional follow-up in traumatic brain injury is to protect the brain from both primary and secondary damage; for this reason, it should be followed closely with multimonitoring methods that are possibly multidisciplinary.

在创伤性脑损伤(TBI)中,可以直接获得脑血流量、脑组织氧合和脑灌注压值的信息。更重要的是,可以通过多维监测和广泛使用的监测方法来了解这些测量值的变化。研究目的:我们旨在评估在我们的儿科重症监护病房(PICU)随访的因TBI而患重症儿童的监测情况。材料和方法:本研究纳入2018年至2020年在我院三级PICU随访的28例头部外伤患者。从回顾性档案记录中获取脑组织氧合、视神经鞘直径(ONSD)、格拉斯哥昏迷评分(GCS)和格拉斯哥预后评分(GOSE)值并进行检查。结果:男性占71.4% (n=20)。当我们根据GCS对TBI进行分类时,50% (n=14)为中度TBI, 50%为重度TBI。预后不良组患者第1天ONSD、nICP均高于预后良好组(ONSD, p=0.01;nICP, p=0.004)。入院第2天,预后不良组的ONSD和nICP显著高于预后良好组(ONSD p=0.002;nICP p= 0.001)。预后良好组和预后不良组第1天和第2天脑组织氧合值均在第2天显著降低(p=0.03, 0.006)。在预后良好组中,与入院时相比,第2天的ONSD和nICP测量值有统计学意义的降低(ONSD p=0.004;结论:外伤性脑损伤患者多维随访的目的是保护脑免受原发性和继发性损伤;出于这个原因,应该密切关注可能是多学科的多监测方法。
{"title":"Evaluation of monitoring critical ill children with traumatic brain injury.","authors":"Merve Misirlioglu, Dincer Yildizdas, Faruk Ekinci, Ozden Ozgur Horoz, Gulen Gul Mert","doi":"10.2478/jccm-2025-0001","DOIUrl":"10.2478/jccm-2025-0001","url":null,"abstract":"<p><strong>Introduction: </strong>In traumatic brain injury (TBI), direct information can be obtained about cerebral blood flow, brain tissue oxygenation and cerebral perfusion pressure values. More importantly, an idea about the changes in these measurements can be obtained with multidimensional monitoring and widely used monitoring methods.</p><p><strong>Aim of the study: </strong>We aimed to evaluate the monitoring of critically ill children who were followed up in our pediatric intensive care unit (PICU) due to TBI.</p><p><strong>Material and method: </strong>Twenty-eight patients with head trauma who were followed up in our tertiary PICU between 2018 and 2020 were included in the study. Cerebral tissue oxygenation, optic nerve sheath diameter (ONSD), Glasgow coma score (GCS) and Glasgow Outcome Score (GOSE) values were obtained from retrospective file records and examined.</p><p><strong>Results: </strong>Male gender was 71.4% (n=20). When we classified TBI according to GCS, 50% (n=14) had moderate TBI and 50% had severe TBI. On the first day in the poor prognosis group, ONSD and nICP were found to be higher than in the good prognosis group (for ONSD, p=0.01; and for nICP, p=0.004). On the second day of hospitalization, the ONSD and nICP were significantly higher in the poor prognosis group than in the good prognosis group (for ONSD p=0.002; and for nICP p= 0.001). Cerebral tissue oxygenation values measured on the first and second days decreased significantly on the second day in both the good and poor prognosis groups (p=0.03, 0.006). In the good prognosis group, a statistically significant decrease was found in ONSD and nICP measurements taken on the 2nd day compared to the measurements taken at the time of hospitalization (for ONSD p=0.004; for nICP p<0.001).</p><p><strong>Conclusion: </strong>The aim of multidimensional follow-up in traumatic brain injury is to protect the brain from both primary and secondary damage; for this reason, it should be followed closely with multimonitoring methods that are possibly multidisciplinary.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"11 1","pages":"78-86"},"PeriodicalIF":0.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Critical Care Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1